Evaxion plans to file 2025 annual report later today

Rhea-AI Summary

Evaxion (NASDAQ: EVAX) will slightly delay filing its 2025 annual report originally planned for Nasdaq opening on March 5, 2026, due to unforeseen technical issues with external vendors related to regulatory filing demands.

The report is finalized and will be filed and published as soon as possible; the investor conference call/webcast is rescheduled to March 6, 2026 at 8:30 ET / 14:30 CET.

News Market Reaction – EVAX

+9.32%

4 alerts

+9.32% News Effect

+4.6% Peak Tracked

-4.3% Trough Tracked

+$2M Valuation Impact

$28.53M Market Cap

1.2x Rel. Volume

On the day this news was published, EVAX gained 9.32%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -4.3% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $28.53M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +9.3% in the session following this news. A strong positive reaction aligns with Eva...

Analysis

The stock moved +9.3% in the session following this news. A strong positive reaction aligns with Evaxion’s history of significant moves around operational updates: prior scientific and collaboration news produced swings up to 19.62% and down 18.26%. This announcement concerns a technical delay to the 2025 annual report filing, with the report stated as finalized and the call shifted to March 6. Investors would likely weigh this against the company’s recent F-1 data, including $3.3M in 2024 revenue and a $10.6M net loss.

Key Figures

Registered ordinary shares: 38,450,000 shares Registered ADSs: 769,000 ADSs Debt cancelled: €3.5 million +5 more

8 metrics

Registered ordinary shares 38,450,000 shares F-1 registration for resale by European Investment Bank

Registered ADSs 769,000 ADSs F-1 registration tied to EIB warrants

Debt cancelled €3.5 million EIB debt-for-warrants settlement in F-1 filing

Potential warrant proceeds DKK 9,612,500 (~$1.5 million) If EIB warrants fully exercised

2024 revenue $3.3 million Reported in F-1 registration statement

2024 net loss $10.6 million Reported in F-1 registration statement

Cash and cash equivalents $10.6 million As of September 30, 2025 in F-1 filing

Total equity $16.6 million As of September 30, 2025 in F-1 filing

Historical Context

5 past events · Latest: Mar 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 02	Earnings timing update	Neutral	+0.3%	Set date and time for 2025 results and business update call.
Jan 13	Platform expansion	Positive	-1.5%	Expanded AI-Immunology™ into autoimmune diseases with cash runway unchanged.
Jan 07	Conference presentation	Positive	+6.7%	Planned 2026 milestones presentation at Biotech Showcase conference.
Dec 19	Collaboration update	Negative	-18.3%	MSD declined EVX-B2 option; Evaxion retains rights and seeks new partner.
Dec 06	Preclinical data	Positive	+19.6%	New EVX-04 AML vaccine data showing strong T-cell responses and tumor control.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Price has generally tracked news tone, with 4 aligned reactions and 1 divergence across the last five events.

Recent Company History

Over recent months Evaxion has mixed operational and strategic news with varied price reactions. Positive scientific and milestone updates, such as new EVX-04 data on Dec 6, 2025, drew strong gains, while collaboration updates on EVX-B2 on Dec 19, 2025 coincided with a sharp decline. Expansion of the AI-Immunology™ platform into autoimmune diseases on Jan 13, 2026 saw a modest negative move despite strategic significance. Today’s technical delay to the 2025 annual report filing follows a prior notice on Mar 2, 2026 about the planned results date and call.

Key Terms

form 6-k, form f-1, form s-8, form f-3, +4 more

8 terms

form 6-k regulatory

"filed a Form 6-K describing two February 2026 warrant grants"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

form f-1 regulatory

"has filed an F-1 to register up to 38,450,000 ordinary shares"

A Form F-1 is the document a non-U.S. company files with U.S. regulators when it wants to sell stock or other securities to U.S. investors. It lays out the company’s business, finances, risks and how the offering will work, acting like a product manual and ingredient list so investors can judge what they’re buying. For investors, it’s a key source of verified information used to compare opportunities and assess potential reward and risk.

form s-8 regulatory

"existing registration statements on Forms S-8, F-3 and F-1"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

form f-3 regulatory

"existing registration statements on Forms S-8, F-3 and F-1"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

warrants financial

"granted 6,544,725 warrants to board members, management and employees"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

articles of association regulatory

"the Articles of Association were amended to reflect the new warrant programs"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

ads financial

"represented by 769,000 ADSs, for resale by the European Investment Bank"

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

registration statements regulatory

"incorporated by reference into several existing registration statements on Forms S-8"

Registration statements are detailed documents companies file with securities regulators when they plan to offer shares or other securities to the public. They act like a recipe and instruction manual, listing a company’s business, finances, management, risks and how the offering will work, so investors can judge value and potential downsides. For investors, these filings provide the official, legally required facts needed to make informed decisions and spot warning signs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.  

The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself. 

As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 ET/14.30 CET.   

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event. 

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event. 

Contact information  

Evaxion A/S 
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai 

About Evaxion  

Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases. 

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development 

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.  

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.  

Forward-looking statement  

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.  

FAQ

Why is Evaxion (EVAX) delaying its 2025 annual report filing on March 5, 2026?

The report filing was delayed due to unforeseen technical issues with external vendors affecting regulatory filing systems. According to Evaxion, the delay concerns vendor technical processes, not the content of the finalized 2025 annual report, which will be filed as soon as possible.

When will Evaxion (EVAX) hold the rescheduled investor conference call and webcast?

Evaxion rescheduled the investor call to Friday, March 6, 2026 at 8:30 ET / 14:30 CET. According to Evaxion, the webcast will be accessible live and a recording will be posted on the company website shortly after the event.

How can investors join the Evaxion (EVAX) conference call on March 6, 2026?

Investors should register in advance to receive dial-in numbers and a unique PIN code to ask verbal questions. According to Evaxion, registration provides the required dial-in details and the call opens 15 minutes before the start time.

Will the content of Evaxion's 2025 annual report be affected by the filing delay?

No, the company said the report itself is finalized and unaffected by the technical delay. According to Evaxion, the issues are limited to external regulatory filing demands and do not change the report content or figures.

Where will the Evaxion (EVAX) webcast recording be available after the March 6 presentation?

The webcast recording will be posted on the company's website shortly after the live event. According to Evaxion, investors can access the recorded presentation on the investor relations section of the Evaxion website following the call.

Who can investors contact for questions about Evaxion's delayed 2025 annual report and webcast?

Investors can contact Mads Kronborg, Vice President Investor Relations & Communication, using the provided phone number and email. According to Evaxion, the contact details are available for inquiries related to the filing delay and the rescheduled webcast.